00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
19:39 , Oct 10, 2018 |  BC Extra  |  Company News

Management tracks: Hamburg joins Alnylam board

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) appointed Margaret Hamburg to its board, effective Jan. 10, 2019. Hamburg is president-elect of the American Association for the Advancement of Science (AAAS), foreign secretary of the National...
19:32 , Sep 7, 2018 |  BC Week In Review  |  Company News

Atara partners with Moffitt Cancer Center to develop CAR T therapies

Atara Biotherapeutics Inc. (NASDAQ:ATRA) partnered with H. Lee Moffitt Cancer Center and Research Institute (Tampa, Fla.) to develop multi‑targeted CAR T immunotherapies to treat cancers with diverse cell types that often become resistant to treatment,...
23:06 , Jun 7, 2018 |  BC Extra  |  Company News

Management tracks: Alder, BIO

Neurology company Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) hired Robert Azelby as president and CEO, effective June 13. Azelby was EVP and chief commercial officer at Juno Therapeutics Inc., which Celgene Corp. (NASDAQ:CELG) acquired. The Biotechnology Innovation...
19:05 , May 18, 2018 |  BC Week In Review  |  Company News

Atara, Memorial Sloan Kettering expand CAR-T deal

Atara Biotherapeutics Inc. (NASDAQ:ATRA) and Memorial Sloan Kettering Cancer Center (New York, N.Y.) expanded a 2014 deal in order to give Atara access to several MSKCC technologies including a CAR T construct and methods for...
22:28 , May 7, 2018 |  BC Extra  |  Company News

Management tracks: Adverum, Evolus

Adverum Biotechnologies Inc. (NASDAQ:ADVM) said President and CEO Amber Salzman has stepped down. CFO and SVP Leone Patterson is acting as interim president and CEO while the gene therapy company searches for a successor. Additionally,...
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
18:24 , Mar 9, 2018 |  BC Week In Review  |  Financial News

Atara raises $150M in follow-on

Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $150 million on Feb. 28 through the sale of 4.3 million shares at $35 in a follow-on underwritten by J.P. Morgan, Cowen, Canaccord Genuity and Mizuho. The price is an...
16:18 , Mar 1, 2018 |  BC Extra  |  Financial News

Atara raises another $150M in latest follow-on

Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $150 million through the sale of 4.3 million shares at $35 in a follow-on underwritten by J.P. Morgan, Cowen, Canaccord Genuity and Mizuho. The price is an 18% discount to...
23:28 , Feb 26, 2018 |  BC Extra  |  Company News

Management tracks: Vertex, Basilea

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said CMO and EVP of Global Medicines Development and Medical Affairs Jeffrey Chodakewitz will retire, effective April 1. He is succeeded by Vertex SVP of Clinical Development and Medical Affairs Reshma...